We are monitoring the impact of COVID-19 on APAC Protein Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5064
Share on
Share on

APAC Protein therapeutics Market Research Report – Segmented By Product, Application, Therapeutic Modalities, & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026

Pulished: April, 2021
ID: 5064
Pages: 145

APAC Protein Therapeutics Market Size (2021 to 2026)

As per the research report, the size of the Asia Pacific Protein Therapeutics market was worth USD 34.33 billion in 2021. It is expected to grow at a CAGR of 7.3% and value USD 48.82 billion by 2026. It captures 20% of the global market.

Protein therapeutics are most often employed in the treatment of chronic ailments like cancer etc. This market has huge potential in the coming years.

Factors such as rising demand for protein treatments, rising prevalence of chronic diseases, and the development of plasma-derived therapies are majorly driving the growth of the APAC protein therapeutics market. Also, the rising frequency of chronic medical disorders is one of the primary reasons driving the market’s growth. 

On the other hand, the increased awareness among the general public of the benefits of protein treatments, such as the low risk of side effects and great efficacy, positively influences the market growth.

 Pharmaceutical companies utilize protein treatments to develop new drugs, and monoclonal antibodies are widely explored and used to treat numerous viral and bacterial disorders.

However, the unexpected outbreak of coronavirus disease presents potential prospects for the protein therapies market. 

During the projected period, rising incidence of chronic diseases such as cancer, cardiovascular disease, and diabetes are expected to fuel the market growth. The acceptance of treatments with great efficiency and low risk of side effects increases among the end-users.

Furthermore, the Asia pacific protein therapeutics market is being propelled forward by increased awareness of protein therapeutics and the growing adoption of plasma-derived medicines to treat chronic diseases. Furthermore, several governments have taken numerous measures to enhance the healthcare sector by creating ideal conditions to help the protein therapies market grow significantly.

However, The market expansion is being stifled by vague government regulations and a clumsy administrative framework. In addition, the high cost of installing and maintaining devices in laboratories is limiting the growth of the APAC protein therapeutics market.

This research report on the APAC protein therapeutics market has been segmented and sub-segmented into the following categories:

By Product:

  • Monoclonal Antibodies

  • Insulin

  • Fusion Protein

  • Erythropoietin

  • Interferon

  • Human Growth Hormone

  • Follicle Stimulating Hormone

By Application:

  • Metabolic Disorders

  • Immunologic Disorders

  • Hematological Disorders

  • Cancer

  • Hormonal Disorders

  • Genetic Disorders

  • Others

By Therapeutic Modalities: 

  • Protein Diagnostics

  • Protein Vaccines

  • Protein Therapeutics with Special Targeting Activity

  • Protein Therapeutics with Enzymatic Or Regulatory Activity

By Country: 

  • India

  • China

  • Japan

  • South Korea

  • Australia

  • New Zealand

  • Thailand

  • Malaysia

  • Vietnam

  • Philippines

  • Indonesia

  • Singapore

  • Rest of APAC

Geographically, as emerging nations become more aware of these revolutionary treatment procedures, the Asia Pacific protein therapeutics market is expected to increase at the fastest rate during the projected period. Due to the rapid increase in chronic diseases, improved consumer knowledge, supporting government policies, modernization of health infrastructure, and population growth in developing nations like China and India in this region. In this region, the rising protein treatments use in emerging economies such as China, India, and Japan, expanding the market for protein therapeutics. 

China recorded the largest share of the APAC protein therapeutics market, and it is projected to account for a predominant share during the forecast period. Developing market enterprises, snowballing research and development in the protein therapies sector, the government’s increasing emphasis on immunization to combat various diseases, and a large target population significantly contribute to market growth. 

Furthermore, one of the emerging countries in the Asia Pacific is India. The Indian protein therapeutics market growth is projected to record a promising share in the coming year. Increasing investments and initiatives by the government through medical tourism, improving the healthcare sector, and increasing the prevalence of chronic diseases are driving the market growth. 

Notable participants dominating the Asia Pacific Protein Therapeutics Market profiled in this report are Baxter International Inc., Eli Lilly, and Company, Abbott Laboratories, Amgen Inc., F. Hoffmann-La Roche Ltd. Other players in the market are Novo Nordisk A/S, Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., and Sanofi.

1. Introduction      

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods

               1.4 General Study Assumptions                 

2. Research Methodology                

               2.1 Introduction   

               2.2 Research Phases                      

    2.2.1 Secondary Research           

    2.2.2 Primary Research 

    2.2.3 Econometric Modelling      

    2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview           

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology  

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)          

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                  

               5.1 Product                       

    5.1.1 Introduction           

    5.1.2 Monoclonal Antibodies      

    5.1.3 Insulin       

    5.1.4 Fusion Protein       

    5.1.5 Erythropoietin       

    5.1.6 Interferon

    5.1.7 Human Growth Hormone  

    5.1.8 Follicle Stimulating Hormone          

    5.1.9 Y-o-Y Growth Analysis, By Product

    5.1.10 Market Attractiveness Analysis, By Product           

    5.1.11 Market Share Analysis, By Product            

               5.2 Therapeutic Modalities                         

    5.2.1 Introduction           

    5.2.2 Protein diagnostics             

    5.2.3 Protein vaccines   

    5.2.4 Protein therapeutics with special targeting activity

    5.2.5 Protein therapeutics with enzymatic or regulatory activity 

    5.2.6 Y-o-Y Growth Analysis, By Therapeutic Modalities  

    5.2.7 Market Attractiveness Analysis, By Therapeutic Modalities

    5.2.8 Market Share Analysis, By Therapeutic Modalities

               5.3 Application                 

    5.3.1 Introduction           

    5.3.2 Metabolic Disorders            

    5.3.3 Immunologic Disorders      

    5.3.4 Hematological Disorders    

    5.3.5 Cancer      

    5.3.6 Hormonal Disorders            

    5.3.7 Genetic Disorders 

    5.3.8 Others      

    5.3.9 Y-o-Y Growth Analysis, By Application         

    5.3.10 Market Attractiveness Analysis, By Application     

    5.3.11 Market Share Analysis, By Application      

6. Geographical Analysis                  

               6.1 Introduction   

    6.1.1 Regional Trends    

    6.1.2 Impact Analysis     

    6.1.3 Y-o-Y Growth Analysis        

                   6.1.3.1 By Geographical Area

                   6.1.3.2 By Product

                   6.1.3.3 By Therapeutic Modalities

                   6.1.3.4 By Application

    6.1.4  Market Attractiveness Analysis      

                   6.1.4.1 By Geographical Area

                   6.1.4.2 By Product

                   6.1.4.3 By Therapeutic Modalities

                   6.1.4.4 By Application

    6.1.5  Market Share Analysis       

                   6.1.5.1 By Geographical Area

                   6.1.5.2 By Product

                   6.1.5.3 By Therapeutic Modalities

                   6.1.5.4 By Application

               6.2 China

               6.3 India  

               6.4 Japan

               6.5 South Korea               

               6.6 Australia                     

7. Strategic Analysis            

               7.1 PESTLE analysis                        

    7.1.1 Political    

    7.1.2 Economic 

    7.1.3 Social        

    7.1.4 Technological        

    7.1.5 Legal         

    7.1.6 Environmental       

               7.2 Porter’s Five analysis   

    7.2.1 Bargaining Power of Suppliers         

    7.2.2 Bargaining Power of Consumers     

    7.2.3 Threat of New Entrants      

    7.2.4 Threat of Substitute Products and Services

    7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis             

               8.1 Abbott Laboratories               

    8.1.1 Overview 

    8.1.2 Product Analysis   

    8.1.3 Financial analysis  

    8.1.4 Recent Developments        

    8.1.5 SWOT analysis       

    8.1.6 Analyst View          

               8.2 Amgen Inc.                

               8.3 Baxter International Inc.                      

               8.4 Eli Lilly and Company  

               8.5 F. Hoffmann-La Roche Ltd.                  

               8.6 Johnson & Johnson                

               8.7 Merck & Co. Inc.                     

               8.8 Novo Nordisk A/S                    

               8.9 Pfizer Inc.                   

               8.10 Sanofi                       

9. Competitive Landscape               

               9.1 Market share analysis 

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations, and Joint Ventures

               9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities               

11. Appendix                

               a) List of Tables                

               b) List of Figures   

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identifying the regions that are still untapped

  • The segment-level analysis in terms of product type along with market size forecasts and estimations to detect key areas of industry growth in detail

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment

  • Competitive landscape analysis lists out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

  1. Asia Pacific Protein Therapeutics Market, By Product, From 2021 to 2026 (USD Billion)

  2. Asia Pacific Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)

  3. Asia Pacific Insulin Market, By Region, From 2021 to 2026 (USD Billion)

  4. Asia Pacific Fusion Protein Market, By Region, From 2021 to 2026 (USD Billion)

  5. Asia Pacific Erythropoietin Market, By Region, From 2021 to 2026 (USD Billion)

  6. Asia Pacific Interferon Market, By Region, From 2021 to 2026 (USD Billion)

  7. Asia Pacific Human Growth Hormone Market, By Region, From 2021 to 2026 (USD Billion)

  8. Asia Pacific Follicle Stimulating Hormone Market, By Region, From 2021 to 2026 (USD Billion)

  9. Asia Pacific Protein Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)

  10. Asia Pacific Metabolic Disorders Market, By Region, From 2021 to 2026 (USD Billion)

  11. Asia Pacific Immunologic Disorders Market, By Region, From 2021 to 2026 (USD Billion)

  12. Asia Pacific Hematological Disorders Market, By Region, From 2021 to 2026 (USD Billion)

  13. Asia Pacific Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  14. Asia Pacific Hormonal Disorders Market, By Region, From 2021 to 2026 (USD Billion)

  15. Asia Pacific Genetic Disorders Market, By Region, From 2021 to 2026 (USD Billion)

  16. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)

  17. Asia Pacific Protein Therapeutics Market, By Therapeutic Modalities, From 2021 to 2026 (USD Billion)

  18. Asia Pacific Protein Diagnostics Market, By Region, From 2021 to 2026 (USD Billion)

  19. Asia Pacific Protein vaccines Market, By Region, From 2021 to 2026 (USD Billion)

  20. Asia Pacific Protein therapeutics with special targeting activity Market, By Region, From 2021 to 2026 (USD Billion)

  21. Asia Pacific Protein therapeutics with enzymatic or regulatory activity Market, By Region, From 2021 to 2026 (USD Billion)

  22. Japan Protein Therapeutics Market, By Product, From 2021 to 2026 (USD Billion)

  23. Japan Protein Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)

  24. Japan Protein Therapeutics Market, By Therapeutic Modalities, From 2021 to 2026 (USD Billion)

  25. China Protein Therapeutics Market, By Product, From 2021 to 2026 (USD Billion)

  26. China Protein Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)

  27. China Protein Therapeutics Market, By Therapeutic Modalities, From 2021 to 2026 (USD Billion)

  28. India Protein Therapeutics Market, By Product, From 2021 to 2026 (USD Billion)

  29. India Protein Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)

  30. India Protein Therapeutics Market, By Therapeutic Modalities, From 2021 to 2026 (USD Billion)

  31. Australia Protein Therapeutics Market, By Product, From 2021 to 2026 (USD Billion)

  32. Australia Protein Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)

  33. Australia Protein Therapeutics Market, By Therapeutic Modalities, From 2021 to 2026 (USD Billion)

  34. South Korea Protein Therapeutics Market, By Product, From 2021 to 2026 (USD Billion)

  35. South Korea Protein Therapeutics Market, By Application, From 2021 to 2026 (USD Billion)

  36. South Korea Protein Therapeutics Market, By Therapeutic Modalities, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample